Vysis LSI ZNF217 SpectrumGold, SpectrumOrange, SpectrumRed FISH Probe Kits
For more information, contact Abbott.
For more information, contact Abbott.
| PRODUCT NAME | UNIT SIZE | ORDER NUMBER | GTIN |
|---|
The Vysis LSI ZNF217 SpectrumGold Probe is intended to determine copy number of ZNF217 on chromosome 20q13.2.
The ZNF217 gene is a candidate oncogene suggested to play a key role during neoplastic transformation. ZNF217 is located at 20q13, a region that is frequently amplified in a variety of tumor types. Amplification of ZNF217 in breast cancer is associated with aggressive tumor behavior and poor clinical prognosis. The Vysis LSI ZNF217 SpectrumOrange Probe was used in a study that indicated distinct differences in the role of genes known to be amplified in female breast cancer and their relevance for the pathogenesis of male breast cancer. FISH was performed on 128 male breast tumors using the Vysis LSI ZNF217 SpectrumOrange Probe in addition to other Vysis probes including, LSI HER-2, LSI CCND1, LSI MYC, and the corresponding centromeric probes. Another study used the Vysis LSI ZNF217 SpectrumOrange Probe to identify gain of ZNF217 as an important abnormality and prognostic factor in larynx tumorigenesis. For this study a tissue microarray consisting of 863 larynx carcinomas was analysed.
The Vysis LSI ZNF217 SpectrumGold Probe is a single, approximately 433 kb, unique sequence probe direct labeled in SpectrumGold, that hybridizes to the 20q13.2 region of hromosome 20 and includes the 16.1 kb ZNF217 gene (chr20:51617017-51633114 March 2006 UCSC Browser).
The Vysis LSI ZNF217 SpectrumOrange Probe is intended to determine copy number of ZNF217 on chromosome 20q13.2.
The ZNF217 gene is a candidate oncogene suggested to play a key role during neoplastic transformation. ZNF217 is located at 20q13, a region that is frequently amplified in a variety of tumor types. Amplification of ZNF217 in breast cancer is associated with aggressive tumor behavior and poor clinical prognosis. The Vysis LSI ZNF217 (20q13.2) SpectrumOrange Probe was used in a study that indicated distinct differences in the role of genes known to be amplified in female breast cancer and their relevance for the pathogenesis of male breast cancer. FISH was performed on 128 male breast tumors using the Vysis SpectrumOrange LSI ZNF217 in addition to other Vysis probes including, LSI HER-2, LSI CCND1, LSI MYC, and the corresponding centromeric probes. Another study used the Vysis LSI ZNF217 (20q13.2) SpectrumOrange Probe to identify gain of ZNF217 as an important abnormality and prognostic factor in larynx tumorigenesis. For this study, a tissue microarray consisting of 863 larynx carcinomas was analysed.
The Vysis LSI ZNF217 SpectrumOrange Probe is a single approximately 433 kb unique sequence probe direct labeled in SpectrumOrange, that hybridizes to the 20q13.2 region of chromosome 20 and includes the 16.1 kb ZNF217 gene.
The Vysis LSI ZNF217 SpectrumRed Probe is intended to determine copy number of ZNF217 on chromosome 20q13.2.
The ZNF217 gene is a candidate oncogene suggested to play a key role during neoplastic transformation. ZNF217 is located at 20q13, a region that is frequently amplified in a variety of tumor types. Amplification of ZNF217 in breast cancer is associated with aggressive tumor behavior and poor clinical prognosis. The Vysis LSI ZNF217 SpectrumOrange Probe was used in a study that indicated distinct differences in the role of genes known to be amplified in female breast cancer and their relevance for the pathogenesis of male breast cancer. Fluorescence in situ hybridization was performed on 128 male breast tumors using the Vysis LSI ZNF217 SpectrumOrange Probe in addition to other Vysis probes including LSI HER-2, LSI CCND1, LSI MYC, and the corresponding centromeric probes. Another study used the Vysis LSI ZNF217 SpectrumOrange Probe to identify gain of ZNF217 as an important abnormality and prognostic factor in larynx tumorigenesis. For this study, a tissue microarray consisting of 863 larynx carcinomas was analyzed.
The Vysis LSI ZNF217 SpectrumRed Probe is a single approximately 433 kb unique sequence probe direct labeled in SpectrumRed, that hybridizes to the 20q13.2 region of chromosome 20 and includes the 17.5 kb ZNF217 gene.
When hybridized with the LSI ZNF217 Probe, a normal cell containing two copies of the 20q13.2 region will exhibit two gold signals. signals. In a cell harboring amplification of the ZNF217 gene or 20q13.2 region, multiple copies of the gold signal will be observed.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.